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Abstract
Background: In the Netherlands, infection with varicella-zoster virus (VZV) is considered a benign common
childhood illness and routine vaccination against VZV is not done. In 1995 it was estimated that 98-100% of the
adult Dutch general population is immune, yet the estimate is based on a database in which a relative small
number of people of non-Dutch ethnic origin were represented. As the city of Amsterdam has large immigrant
communities originating from various subtropical and tropical countries, such as Morocco, Surinam, and Turkey
with probably lower VZV transmission, this study aimed to estimate the seroprevalence of VZV IgG antibodies (anti-
VZV) among various ethnic groups in Amsterdam, and identify factors associated with seronegative VZV status.
Methods: The study was a cross-sectional survey of the Amsterdam population (2004), and the study sample was
stratified by age and ethnicity, with deliberate oversampling of minority ethnic groups. Serum samples obtained
from 1,341 residents in 2004 were tested for antibodies to VZV. Basic demographic data (gender, age, country of
birth, age at immigration and number of children) were also available.
Results: The anti-VZV seroprevalence in the overall Amsterdam population was estimated to be 94% (95%
confidence intervals; 92–96%). Regarding ethnic origin, first generation immigrants (Moroccan immigrants 90%,
Surinamese or Antillean immigrants 91%, and Turkish 92%), especially those that migrated after the age of 11 years,
were more likely to be anti-VZV seronegative compared to those arriving at an earlier age or those born in the
Netherlands (97–98%). Both ethnic origin and generation of immigration were positive predictors for IgG
seronegativity to VZV (p<0.015). No other predictors for seronegativity were found.
Conclusion: The results of this study imply that about 4–8% of the general adult Amsterdam population is still
susceptible to infection with VZV, and that susceptibility is even higher in some immigrant groups. When assessing
the risk of infection after VZV exposure alertness is needed for vulnerable persons like pregnant women, patients
with hematological malignancies or organ transplants in particular among first-generation immigrants.
Background
In the Netherlands, primary varicella infection (chicken
pox) is considered a benign common childhood illness.
After a first infection with varicella-zoster virus (VZV),
immunity is regarded as life-long [1]. In later life, reacti-
vation of latent VZV established in cells of the dorsal
root ganglia after primary infection, may cause herpes
zoster (shingles). Currently, routine vaccination against
VZV is not done, although its introduction in the na-
tional immunization programme is now being evaluated
[2].To assess the risk of infection after VZV exposure
sound epidemiological data are needed to identify risk
groups associated with VZV seronegativity.
VZV circulates widely in the Dutch population, and ex-
posure to the virus is relatively frequent. The risk for VZV
infection is highest in pre-school children aged 1–5 years,
and by the age of 5, at least 93% of the children have VZV
antibodies. According to a national population-based VZV
seroprevalence study (1995–1996), almost all Dutch adults
(98–100%) have antibodies against VZV, yet that study
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included relatively few residents of non-Dutch origin [3-5].
This finding of near-total VZV seropositivity in the adult
Dutch population, and the high risk of infection in young
children is typical for a country in a region with a temper-
ate climate. For unclear reasons the epidemiology of VZV
shows great regional and seasonal variation. In subtropical
and tropical climates the overall incidence of VZV infec-
tions is lower and infection occurs often at a later age;
physical factors like different levels of ultra-violet radiation
may play a role [1,6,7]. As the city of Amsterdam has large
immigrant communities originating from various subtrop-
ical and tropical countries, such as Morocco, Surinam, and
Turkey with probably lower VZV transmission, this study
aimed to estimate the seroprevalence of VZV IgG anti-
bodies (anti-VZV) among various ethnic groups in Amster-
dam, and identify factors associated with seronegative VZV
status.
Methods
Study population and sampling procedure
The data used for this study were obtained from a cross-
sectional population-based health survey (the Amsterdam
Health Monitor, or AHM). The survey was carried out in
2004 by the Amsterdam Public Health Service (GGD) in
collaboration with the National Institute for Public Health
and the Environment (RIVM). Amsterdam consists of thir-
teen districts and the sample for the survey was drawn
from five of them. These five contain a population that was
representative concerning socioeconomic status and ethni-
city for the total population of Amsterdam. The survey was
approved by the Medical Ethics Committee of the
Academic Medical Centre. The sample was stratified by
ethnic background (Dutch, Moroccan, Turkish and other
ethnic groups) and five age groups (18–34, 35–44, 45–54,
55–64, and 65 years or older). Within each stratum a ran-
dom sample was drawn. The Turkish and Moroccan ethnic
groups were oversampled to ensure sufficient numbers of
individuals from these groups. Data were weighted to cor-
rect for oversampling by ethnic groups. After weighting the
data for age, gender and ethnicity, respondents appeared to
have an annual income and unemployment rate that was
comparable to that of the total population of Amsterdam in
2004. The overall response rate among ethnic Dutch,
Turkish and Moroccan subjects was 45%. More details on
the survey are described elsewhere [8,9].
Respondents were invited for an interview and medical
examination in a community health centre. All inter-
views were conducted in the language of choice of the
respondent (i.e. Dutch, Turkish, Moroccan-Arabic or
Berber). From all the issues that were addressed the fol-
lowing variables were considered pertinent to the
current study: sex, age, country of birth of the partici-
pant and his/her parents, age at the time of migration,
and the number and age of children living with the
participant currently and/or in the past. Participants
were classified into five ethnic groups (Dutch,
Surinamese or Antillean, Turkish, Moroccan, and other),
according to the self-reported country of birth and the
country of birth of the respondent's mother or father.
Furthermore, participants of non-Dutch ethnic origin
were classified as first- or second-generation immigrants
depending on their own country of birth. Those born in
the Netherlands were considered as second-generation
and all others as first-generation immigrants.
Participants were requested to provide a blood sample.
These were collected, after obtaining written informed
consent, and were stored at 7°C within 30 minutes, then
centrifuged and frozen at −80°C within 48 hr. Seventy-
nine per cent of the participants (n = 1,376) donated a
blood sample for the serum repository.
Serological assays
Plasma samples were tested for IgG-class antibodies to
VZV by means of quantitative enzyme immunoassays.
The assays were performed in the Public Health Labora-
tory in Amsterdam according to the instructions of the
manufacturer. The serological test was a microplate
enzyme-linked immunosorbent assay system that uses
purified antigen (cell lysate of a human fibroblast cell
line, VZV wild strain) to detect VZV IgG (EUROIM-
MUN Anti-Varicella-Zoster-Virus IgG-ELISA; Medizi-
nische Labordiagnostika AG, Lübeck, Germany).
In estimating anti-VZV seroprevalence, only samples
with a positive result were considered immune. All nega-
tive and equivocal test results (according to the manu-
facturer all results between 80 and 110 mIU/ml) were
considered as not immune. We thereby increased the
specificity and reduced the number of false positive
results. As the purpose of this study was to establish fac-
tors associated with VZV susceptibility, reduced assay
sensitivity is preferable to reduced specificity [10].
Statistical analysis
In order to obtain results representative for the adult
population in Amsterdam, prevalences and confidence
intervals of 95% (95%CI) corrected for stratification were
calculated using the complex samples modules of SPSS,
version 17 (SPSS Inc., Chicago, Illinois, USA). In these
analyses data were weighted for age, sex and ethnic ori-
gin, using a weighing method which corrected the over-
sampling by ethnic groups as described elsewhere
[8,11,12]. Prevalences (P) and odds ratios (OR) were esti-
mated in the general Amsterdam population by taking
into account the study design using Intercooled Stata
11.1 for Windows (Stata Corp., College Station, Texas,
USA). Prevalences were compared using the Chi-square
test; and a P-value of <0.05 was considered as
significant.
Rijckevorsel et al. BMC Infectious Diseases 2012, 12:140 Page 2 of 8
http://www.biomedcentral.com/1471-2334/12/140
Results
Characteristics of the study sample
For this study, 97.5% (1,341/1,376) of the collected blood
samples were available for laboratory analysis. Table 1
shows the characteristics of the 1,341 participants who
were included. The table shows both the distribution in
the study sample (non-weighted), and the estimated dis-
tribution representing the Amsterdam population. The
study sample consisted of 619 men (46%) and 717
women (54%). Age ranged from 17 to 90 years. The me-
dian age for men was 52 years (interquartile range (IQR)
41–62 years) and for women 47 years (IQR 37–58 years).
Most participants were of Dutch (33%), Turkish (24%),
or Moroccan (21%) ethnic origin. Within ethnic groups,
there was an unequal distribution between the sexes for
participants of Surinamese and Antillean ethnic origin
(71% was female), for participants of Dutch ethnic origin
(59% was female), and for participants of Moroccan eth-
nic origin (57% was male). Of all 1,341 participants 61%
(814) were born outside the Netherlands, of which the
majority was first-generation Turkish (306) or Moroccan
immigrant (262). Other first-generation immigrants
came often from the Republic of Surinam and the Neth-
erlands Antilles (78) or from Indonesia (32). The median
age at immigration was 25 years (range 0–76 years), and
only a minority (64 or 8%) of the immigrants came to
live in the Netherlands before the age of 11 years. Only
4% (59) were second-generation immigrants. Half of the
participants (47%) had one or more children (median 2
children, range 1–10 children), and 29% none. For 23%
of the group, data on having children were missing.
Seroprevalence of anti-VZV in the Amsterdam population
Table 2 gives an overview of the test results and the esti-
mated anti-VZV seroprevalence by demographic charac-
teristics. The anti-VZV seroprevalence is shown both
non-weighted, representing the study sample, and
weighted, representing the Amsterdam population. The
anti-VZV seroprevalence in the overall Amsterdam
population was estimated to be 93.8% (95% CI 91.6–
95.5%). Regarding ethnic origin, seroprevalence was low-
est among first-generation immigrants (Moroccan immi-
grants 90%, Surinamese or Antillean immigrants 91%,
and Turkish 92%) compared to those born in the Neth-
erlands (Dutch ethnic origin and second-generation
immigrants 97–98%). Among the first-generation immi-
grants, those that migrated before the age of 11 were
more likely to be seropositive, than those that migrated
at a later age (P< 0.001).
Predictors for IgG seronegativity to VZV in the study
sample
The results of the univariable analysis for IgG seronega-
tivity to VZV are shown in Table 3. All negative and
equivocal test results were considered as IgG seronega-
tive. Both ethnic origin and generation of immigration
were positive predictors for IgG seronegativity to VZV.
When considering the ethnic origin, people of Moroccan
and Turkish ethnic origin were 2.5 times more likely to
be seronegative compared to people from Dutch ethnic
origin (P = 0.013). Almost 10% of all first-generation
immigrants from Morocco and Turkey were anti-VZV
seronegative (P = 0.015). Immigrants that migrated after
the age of 10 were more likely to be seronegative com-
pared to those that migrated at a younger age and those
born in the Netherlands (P = 0.0001). No other predic-
tors for seronegativity were found.
Discussion
Our study shows a high seroprevalence (94%) of VZV
IgG antibodies in the overall adult Amsterdam popula-
tion (95%CI 92–96%), which is in line with other sero-
prevalence estimates in adults living in temperate zones
[3,5,13-19]. A comparative sero-epidemiology study of
anti-VZV in 11 countries in the European region found
that seroprevalence was above 90% in all countries, ex-
cept for Italy (88.8%)[5] . The estimated seroprevalence
in Amsterdam is rather low, compared to the near-total
VZV seropositivity (97–100%) in the adult Dutch popu-
lation, but probably representative for a highly urbanized
area. In a national population-based seroprevalence
study in 1995, a significantly lower seroprevalence
(93.6%; 95%CI 91.7–95.8%) was found in highly urba-
nized municipalities, compared to rural regions (95.9%;
95%CI 95.2–96.6%) [Personal communication; H. de
Melker, Data from 'PIENTER 1995–1996']. Urbanization
of< 2500 addresses per square kilometer (sq.km) was an
independent predictor for seropositivity of VZV com-
pared to urbanization ≥2500 addresses per sq. km (OR
2.1; 95% CI 1.1–3.7) [3]. The difference was not easily
explained [3,5,13,16,20,21].
One explanation for this difference may be the ethnic
diversity present in urban populations. The city of Am-
sterdam has large migrant communities, with people ori-
ginating from various subtropical and tropical countries,
which are known to have less VZV transmission. In tem-
perate regions, VZV causes annual epidemics among
susceptible household members, in day care centers, and
in schools, resulting in high seroprevalence. In warmer
climates, VZV infection is less frequent and as many as
50% of young adults in tropical countries may never
have had a primary VZV infection [1,5,7,22]. In this
study, the relatively low anti-VZV seroprevalence in the
Amsterdam adult population is explained by the pres-
ence of susceptible immigrants. First-generation immi-
grants did have a significantly lower seroprevalence than
persons who were born in the Netherlands. On average,
first-generation immigrants had a 2 times higher risk of
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being anti-VZV seronegative. Furthermore there was a
positive association between anti-VZV seroprevalence
and the age of migration. In this study, the median age
at immigration was 25 years, and most participating
immigrants (665 or 84%) migrated more than 11 years
ago (data not shown). Immigrants who migrated after
the age of 11 years were more likely to be seronegative
compared to those that immigrated at a younger age. It
Table 1 Characteristics of 1,341 participants of the Amsterdam Health Monitoring Survey, 2004
Characteristics
Study sample Amsterdam adult population
n (%) (Estimated proportion)
Total 1,341
Sex
Female 717 (53.5) 50.3
Male 619 (46.2) 49.7
Sex missing 5 (0.4) -
Age category
18–34 212 (15.8) 35.1
35–44 291 (21.7) 23.8
45–54 325 (24.2) 17.1
55–64 279 (20.8) 12.0
65 and older 224 (16.7) 12.0
Age missing 10 (0.7) -
Ethnic origin
Dutch 437 (32.6) 53.5
Moroccan 275 (20.5) 6.9
1st generation, Moroccan 262 - -
Surinamese or Antillean 88 (6.6) 9.3
1st generation, Surinamese or Antillean 78 - -
Turkish 319 (23.8) 4.4
1st generation, Turkish 306 - -
Other ethnic origin 212 (15.8) 25.9
1st generation, other ethnic origin 189 - -
Ethnic origin missing 10 (0.7) -
Immigration status
Autochthonous (born in the Netherlands) 516 (38.5) 64.4
Immigrated at age≤ 10 years 64 (4.8) 5.8
Immigrated at age> 10 years 721 (53.8) 29.8
Immigrated at unknown age 32 (2.4) -
Country of birth missing 8 (0.6) -
Having children
Yes 634 (47.3) 55.7
No 394 (29.4) 44.3
Missing 313 (23.3) -
Number of children (n= 1,028)
0 394 (38.3) 44.8
1 203 (19.7) 21.6
2 239 (23.2) 22.0
3 or more 176 (17.1) 11.6
Number of children missing 16 (1.2) -
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Table 2 Prevalence of VZV IgG antibodies by demographic characteristics among 1,341 Amsterdam residents aged
18 years and older, 2004
Study sample The overall Amsterdam population
n % negative % equivocal % positive % anti-VZV seropositive (95% CI) P-value
Total 1,341 4.1 2.8 93.1 93.8 (91.6–95.5)
Sex 0.29
Male 619 4.2 2.9 92.9 92.8 (89.0–95.4)
Female 717 4.0 2.8 93.2 94.8 (92.2–96.6)
Age category 0.42
18–34 years 212 4.7 2.4 92.9 92.0 (86.3–95.5)
35–44 years 291 4.1 3.4 92.4 95.0 (90.8–97.3)
45–54 years 325 4.9 3.1 92.0 93.5 (89.3–96.1)
55–64 years 279 2.2 2.5 95.3 96.4 (92.4–98.4)
65 years and older 224 4.5 2.7 92.9 94.8 (89.9–97.4)
Age missing 10 10.0 0 90.0 -
Ethnic origin 0.03
Dutch 437 2.1 1.8 96.1 96.6 (94.3–98.0)
Surinamese and Antillean 89 5.6 1.1 93.3 93.0 (80.2–97.8)
Turkish 319 4.7 4.7 90.6 91.8 (87.1–94.8)
Moroccan 275 5.8 3.6 90.6 89.7 (82.9–94.0)
Other 211 4.7 1.9 93.6 90.0 (82.8–94.3)
Ethnic origin missing 10 0 0 100 -
Generation
Dutch 437 2.1 1.8 96.1 96.6 (94.3–98.0) 0.002
1st generation. Surinamese or Antillean 78 6.4 1.3 92.3 90.6 (74.7–96.9)
1st generation. Turkish 306 4.6 4.9 90.5 91.5 (86.5–94.7)
1st generation. Moroccan 262 5.7 3.8 90.5 90.1 (83.5–94.2)
Other 1st generation 189 5.3 2.1 92.6 87.9 (79.7–93.0)
2nd generation immigrants 59 3.4 0 96.6 98.3 (91.3–99.7)
Ethnic origin missing 10 0 0 100 -
Immigration status 0.02
Autochthonous (born in the Netherlands) 516 2.1 1.6 96.3 -
Immigrated at age> 10 years 721 5.7 4.0 90.3 86.3 (80.4–90.7)
Immigrated at age≤ 10 years 64 1.6 1.6 96.9 97.5 (87.8–99.5)
Immigrated at unknown age 32 6.3 0 93.8 -
Country of birth missing 8 0 0 100 -
Children 0.80
No 394 4.1 2.8 93.2 93.3 (88.7–96.1)
Yes 634 4.3 3.3 92.4 94.7 (91.1–96.9)
Data on having children missing 313 3.8 1.9 94.3 -
Number of children (n =1,028) 0.94
0 394 4.1 2.8 93.2 93.3 (88.7–96.1)
1 203 4.4 2.0 93.6 94.9 (88.2–97.9)
2 239 5.0 3.8 91.2 94.7 (87.5–97.8)
3 or more 176 3.4 4.5 92.1 93.6 (84.2–97.5)
Number of children missing 16 0 0 100 -
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Total 1,341 93 6.9 (5.6–8.4)
Sex 0.84
Male 619 44 7.1 1
Female 717 49 6.8 0.96 (0.6–1.5)
Age category 0.52
18–34 years 212 15 7.1 1
35–44 years 291 22 7.6 1.07 (0.5–2.1)
45–54 years 325 26 8.0 1.14 (0.6–2.2)
55–64 years 279 13 4.7 0.64 (0.3–1.4)
65 years and older 224 16 7.1 1.01 (0.5–2.1)
Age missing 10 1 10.0 -
Ethnic origin 0.013
Dutch 437 17 3.9 1
Surinamese or Antillean 89 6 6.7 1.79 (0.7–4.7)
Turkish 319 30 9.4 2.56 (1.4–4.7)
Moroccan 275 26 9.5 2.58 (1.4–4.8)
Other 211 14 6.6 1.76 (0.8–3.6)
Ethnic origin missing 10 0 0 -
Generation
Dutch 437 17 3.9 1
1st generation, Surinamese or Antillean 78 6 7.7 2.06 (0.8–5.4)
1st generation, Turkish 306 29 9.5 2.59 (1.4–4.8)
1st generation, Moroccan 262 25 9.5 2.61 (1.4–4.9)
Other 1st generation 189 14 7.4 1.98 (1.0–4.1)
2nd generation immigrants 59 2 3.4 0.87 (0.2–3.9)
Ethnic origin missing 10 0 0 -
Immigration status < 0.0001
Autochthonous (born in the Netherlands) 516 19 3.7 0.36 (0.2–0.6)
Immigrated at age> 10 years 721 70 9.7 1
Immigrated at age≤ 10 years 64 2 3.1 0.3 (0.1–1.3)
Immigrated at unknown age 32 2 6.3 -
Country of birth missing 8 0 0 -
Children 0.57
No 394 27 6.9 1
Yes 634 48 7.6 1.11 (0.7–1.8)
Data on having children missing 313 18 5.8 0.83 (0.5–1.5)
Number of children (n =1,028) 0.75
0 394 27 6.9 1
1 203 13 6.4 0.93 (0.5–1.8)
2 239 21 8.9 1.31 (0.7–2.4)
3 or more 176 14 8.0 1.17 (0.6–2.3)
Number of children missing 16 0 0 -
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is likely that new immigrants, especially the children, ex-
perience VZV infection after settling in the Netherlands,
yet data on the incidence of VZV in immigrants in the
Netherlands are lacking. A good number of Surinamese
people who migrated to the Netherlands after the inde-
pendence of Surinam in 1975, were referred to the out-
patient department for sexually transmitted infections
because of a vesicular rash, which was thought to be sec-
ondary syphilis but turned out to be chickenpox [Per-
sonal communication; A, van den Hoek]. Also, an
outbreak of chickenpox among West-Indians residing in
the Netherlands has been described [23]. Several surveys
in other countries describe a low seroprevalence in
immigrants and outbreaks of chickenpox among newly
arrived migrants [24-27]. As in this study the only three
variables eligible for inclusion into a multivariable model
(ethnic origin; ethnic origin & generation; immigration
status) were nearly identical (‘ethnic origin and ethnic
origin & generation’) or collinear (‘immigration status’
and ‘ethnic origin’), a multivariable analysis was not
feasible.
Other studies have described that anti-VZV seropreva-
lence may be related to household composition (≥ 4 per-
sons) and school attendance by a household member
[3,6,28-30] . However, in this study no association be-
tween anti-VZV seroprevalence and having children or
the number of children was found.
In this study, we increased the specificity of the test by
considering those with equivocal test results as non-
immune. This may have led to an underestimate of the
true anti-VZV seroprevalence and thus the immunity in
the Amsterdam population, and overestimated the VZV
susceptibility. However, as the aim of this study was to
identify factors associated with VZV susceptibility, and
in order to reduce the number of false positives, this ap-
proach seems justified. A subsidiary analysis in which
the equivocal test results were considered as false nega-
tive showed similar, although less significant outcomes
(data not shown).
The relatively low response rate of the AHM (45%)
and its sampling methods may be considered as poten-
tial sources of bias, which may have affected the results
of this study. However, the oversampling and non-
response bias by ethnic groups were addressed by weigh-
ing the data by sex, age, and ethnicity. A non-responders
survey showed that the sample appeared to be represen-
tative of the population on most health determinants
[9]. Furthermore, a direct association between VZV in-
fection and response to the AHM seems unlikely. For
these reasons the weighted VZV prevalence may be con-
sidered representative for the whole adult population of
Amsterdam.
The introduction of a two-dose universal childhood
VZV vaccination programme in the Netherlands is being
considered. In terms of health policies and the cost-
effectiveness of the introduction of a universal vaccin-
ation programme for VZV, the finding of 4–8% of adult
susceptibles in Amsterdam should be taken into ac-
count. One of several unresolved questions is the impact
of a VZV vaccination programme on the incidence of
herpes zoster. Another issue related to cost-effectiveness
is the uncertainty of the burden of disease of VZV in
children [2]. Compared to neighboring countries, the
Netherlands reports lower rates of complications of
chickenpox in children [31]. With a universal childhood
programme a shift in the age of primary VZV infection
from childhood to adolescents and adults is likely to
occur [5,32-35]. Primary VZV in adults and adolescents
have, like pregnant women and immune-compromised
individuals, an increased risk of complications
[1,29,36,37]. As in the Netherlands chickenpox is not a
notifiable disease, little is known on the incidence of pri-
mary VZV infection or its complications in adults, and
the current overall burden of VZV infection in the adult
population cannot be estimated. Improved surveillance
is needed as a universal childhood vaccination
programme will only change the risk of infection in
VZV-negative adults long after its introduction.
Conclusion
In conclusion, the results of this study imply that about
4-8% of the general adult Amsterdam population is still
susceptible to infection with VZV, and that susceptibility
is even higher in some immigrant groups. When asses-
sing the risk of infection after VZV exposure alertness is
needed for vulnerable persons like pregnant women,
patients with hematological malignancies or organ trans-
plants in particular among first-generation immigrants.
[38].
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